Compare VTOL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | SDGR |
|---|---|---|
| Founded | 1948 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2011 | 2020 |
| Metric | VTOL | SDGR |
|---|---|---|
| Price | $41.66 | $29.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $58.00 | $21.00 |
| AVG Volume (30 Days) | 233.8K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | 34.58 | ★ 45.14 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,490,512,000.00 | $255,869,000.00 |
| Revenue This Year | $11.64 | $0.76 |
| Revenue Next Year | $5.59 | $4.60 |
| P/E Ratio | $36.32 | ★ N/A |
| Revenue Growth | 5.30 | ★ 23.29 |
| 52 Week Low | $35.03 | $10.95 |
| 52 Week High | $50.38 | $30.45 |
| Indicator | VTOL | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 37.66 | 77.77 |
| Support Level | $41.28 | $17.58 |
| Resistance Level | $47.03 | N/A |
| Average True Range (ATR) | 1.40 | 1.69 |
| MACD | -0.29 | 0.92 |
| Stochastic Oscillator | 20.65 | 89.47 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers are in the UK, Norway, the USA, Nigeria, and Others. The offshore energy customers use services to transport personnel to, from and between offshore energy installations. The majority of revenue is generated from Offshore Energy Services.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.